Swiss Cancer League

Recent papers from Swiss Cancer League

1. Sex, Timing, and Outcomes of Curative-Intent ImmunotherapyJAMA Network Open · 2026
2. Validation of the advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the GHSG HD21 trialHemaSphere · 2026
3. AI performance varies considerably across mammography devices: a multi-site and multi-vendor retrospective studyInsights into Imaging · 2026
4. Impact of Postoperative Antithrombotic Treatment on Patency and Survival After Open Posterior Popliteal Artery Aneurysm Repair: A Multicenter Retrospective Cohort Analysis from the PARADE StudyJournal of Clinical Medicine · 2026
5. How Many Attended the Oncogenetic Consultation, When, and Who?: A Population-Based Study Among Relatives of French Patients With CancerCancer Nursing · 2026
6. Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19Journal of Clinical Oncology · 2026
7. NoLEEta: No chemotherapy in intermediate-risk HR+ HER2− early breast cancer treated with ribociclib in the adjuvant setting—A non-inferiority phase III trial.Journal of Clinical Oncology · 2026
8. Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors: A multicenter phase Ib/IIa trial with expansion cohorts in melanoma and soft tissue sarcoma patients (SAKK 66/17).Journal of Clinical Oncology · 2026
9. Prevalence of symptomatic skeletal events (SSE) with reduced denosumab (Dmab) dose density (every 12 weeks versus every 4 weeks): A randomized phase III non-inferiority trial SAKK 96/12 REDUSE.Journal of Clinical Oncology · 2026
10. Intravesical recombinant BCG combined with chemo-immunotherapy (chemo-IO) as perioperative therapy for patients with muscle-invasive bladder cancer (MIBC): Primary analysis of SAKK 06/19.Journal of Clinical Oncology · 2026
11. 24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial.2026
12. European expert consensus on cancer recurrence and progression data collection by population based cancer registriesENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2026
13. Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14)European Urology Oncology · 2026
14. 371P System dynamics analysis of access pathways and hurdles for ctDNA-based MRD testing in solid tumorsESMO Open · 2026
15. Abstract PS5-08-16: Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: Early observations from INVINCIBLE-4-SAKK 66/22 (NCT06358573), a Phase II Randomized Controlled TrialClinical Cancer Research · 2026
16. Abstract RF2-07: Nodal disease burden in patients with clinically node-positive breast cancer undergoing tailored axillary surgery with or without axillary dissection in the neoadjuvant and upfront surgery setting: pre-planned TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)Clinical Cancer Research · 2026
17. Survival After Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell CarcinomaBritish journal of surgery · 2026
18. Conditional recurrence-free survival after curative resection of esophageal cancer: Integrated analysis of individual patient data from 11 randomized controlled trials.Journal of Clinical Oncology · 2026
19. Breast cancer incidence, by stage at diagnosis, and mortality in 21 European countries in the era of mammography screening: an international population-based studyThe Lancet Regional Health - Europe · 2025
20. First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastasesLung Cancer · 2025